Cochrane Abstracts
Dose reduction and discontinuation of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Dose Reduction and Discontinuation of Biologic and Targeted Synthetic disease‐modifying Anti‐rheumatic Drugs (DMARDs) in People With Axial Spondyloarthritis and Low Disease Activity." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438173/all/Dose_reduction_and_discontinuation_of_biologic_and_targeted_synthetic disease‐modifying_anti‐rheumatic_drugs__DMARDs__in_people_with_axial_spondyloarthritis_and_low_disease_activity.
Dose reduction and discontinuation of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438173/all/Dose_reduction_and_discontinuation_of_biologic_and_targeted_synthetic disease‐modifying_anti‐rheumatic_drugs__DMARDs__in_people_with_axial_spondyloarthritis_and_low_disease_activity. Accessed April 26, 2025.
Dose reduction and discontinuation of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438173/all/Dose_reduction_and_discontinuation_of_biologic_and_targeted_synthetic disease‐modifying_anti‐rheumatic_drugs__DMARDs__in_people_with_axial_spondyloarthritis_and_low_disease_activity
Dose Reduction and Discontinuation of Biologic and Targeted Synthetic disease‐modifying Anti‐rheumatic Drugs (DMARDs) in People With Axial Spondyloarthritis and Low Disease Activity [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 April 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438173/all/Dose_reduction_and_discontinuation_of_biologic_and_targeted_synthetic disease‐modifying_anti‐rheumatic_drugs__DMARDs__in_people_with_axial_spondyloarthritis_and_low_disease_activity.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dose reduction and discontinuation of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity
ID - 438173
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438173/all/Dose_reduction_and_discontinuation_of_biologic_and_targeted_synthetic disease‐modifying_anti‐rheumatic_drugs__DMARDs__in_people_with_axial_spondyloarthritis_and_low_disease_activity
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
